Fresenius Medical Care Stock Holds Steady Amid Analyst Cautiousness
Fresenius Medical Care's stock price held steady at around EUR 39.03 on Xetra as of September 13, 2026, despite analysts' cautious views. The dialysis specialist has been trading below its earlier highs, but without a significant price movement.
According to analyst ratings from early September 2026, several institutions have expressed caution about the shares. JPMorgan Chase & Co. rates Fresenius Medical Care stock Underweight, indicating limited upside potential. Jefferies & Company Inc. also has an Underperform rating dated August 7, 2026.
In contrast, DZ Bank issued a Kaufen (Buy) rating on August 6, 2026, while Barclays Capital set the stock at Equal Weight on the same date. However, the balance of ratings still tips towards caution, with more bearish or neutral assessments than positive ones.